Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLA | P06280 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | ESR1 | P03372 | 1/20 | 0.32 |
| ▸ | PGR | P06401 | 1/20 | 0.32 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.32 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.32 |
| ▸ | AR | P10275 | 1/20 | 0.32 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.32 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.32 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4266329 | 1.00 | GLA (0.33) | GLALMNAESR1PGRCHRM2 | |
| SCHEMBL3726007 | 0.73 | ESR1 (0.33) | GLALMNAESR1PGRCHRM2 | |
| SCHEMBL6899350 | 0.73 | ESR1 (0.33) | GLALMNAESR1PGRCHRM2 | |
| SCHEMBL10203319 | 0.73 | ESR1 (0.31) | ESR1PGRCHRM2ADORA3AR | |
| SCHEMBL14307786 | 0.71 | — | — | |
| SCHEMBL3758701 | 0.71 | ESR1 (0.39) | ESR1PGRCHRM2ADORA3AR | |
| SCHEMBL5191282 | 0.71 | ESR1 (0.39) | ESR1PGRCHRM2ADORA3AR | |
| SCHEMBL5191287 | 0.71 | ESR1 (0.39) | ESR1PGRCHRM2ADORA3AR | |
| SCHEMBL3758703 | 0.71 | ESR1 (0.39) | ESR1PGRCHRM2ADORA3AR | |
| SCHEMBL3758711 | 0.71 | ESR1 (0.39) | ESR1PGRCHRM2ADORA3AR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2011134539-A1 | USE OF OXYLIPINS AS SAFENERS AND SAFENING HERBICIDAL COMPOSITIONS COMPRISING OXYLIPINS | BASF SE (DE) | 2011-11-03 | — | — | WO | disclosed |